Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Gastroenterology

Long-Term Monitoring and Preventing Complications

At a Glance

Long-term management of peptic esophagitis focuses on monitoring for complications like Barrett's esophagus and strictures. The cancer risk from non-dysplastic Barrett's is extremely low, and routine endoscopic surveillance ensures any cellular changes are caught and treated early.

For most people with chronic acid reflux, the journey doesn’t end with a single diagnosis. Long-term management involves monitoring for potential complications, the most significant being Barrett’s Esophagus (BE) and esophageal strictures.

While these terms can sound frightening, modern medical guidelines and minimally invasive treatments have transformed these conditions into manageable “survivorship” journeys rather than immediate crises.

Understanding Barrett’s Esophagus

Barrett’s Esophagus occurs when the body, in an attempt to protect itself from chronic acid, replaces the normal lining of the esophagus with tissue that is more like the lining of the small intestine [1].

  • The Cancer Connection: The main concern with BE is that this new tissue can occasionally develop “dysplasia” (abnormal cells) which may eventually progress to esophageal adenocarcinoma (cancer) [2].
  • The Real Risk: For patients with non-dysplastic Barrett’s (no abnormal cell changes), the annual risk of progression to cancer is very low, often estimated between 0.1% and 0.3% [2][3].

2022 Surveillance Guidelines

To manage this low but present risk, organizations like the American College of Gastroenterology (ACG) have established clear surveillance intervals [4].

  • Non-Dysplastic BE: If your biopsies show no abnormal cells, a follow-up endoscopy is typically recommended every 3 to 5 years [4][5].
  • Low-Grade Dysplasia (LGD): If “mildly” abnormal cells are found, your doctor may recommend surveillance every 6 to 12 months or suggest a treatment to remove the cells [6][7].
  • High-Grade Dysplasia (HGD): If “severely” abnormal cells are found, Endoscopic Eradication Therapy (EET) is now the preferred standard of care [8].

Treating Complications Without Major Surgery

If complications do arise, today’s treatments are far less invasive than they were in the past:

  1. Ablation (RFA): For those with dysplasia, Radiofrequency Ablation uses heat to destroy the abnormal lining, allowing healthy tissue to grow back. This is highly effective and avoids the need for major surgery like removing the esophagus (esophagectomy) [9][8].
  2. Dilation for Strictures: Chronic inflammation can cause the esophagus to narrow, forming a stricture that makes swallowing difficult [10]. These are typically treated with endoscopic dilation, where a doctor uses a small balloon or dilator to gently widen the passage [11][12].

Factors That Increase Your Risk

Research has identified specific groups who may need to be more vigilant:

  • Chronic Kidney Disease (CKD): Patients with early-stage CKD have a higher prevalence of GERD and a significantly higher risk of developing esophageal strictures [13].
  • Medication Side Effects: Certain common medications, such as SSRIs or TCAs used for mood and sleep, have been associated with an increased risk of stricture formation [14].

Navigating “Scan Anxiety” and Survivorship

Living with a chronic condition that requires lifelong monitoring can take a psychological toll. “Scan anxiety”—the stress felt before a scheduled endoscopy—is a common experience for patients in surveillance programs.

However, it is important to remember that surveillance is a success story. Because you are being monitored, any changes in your esophagus are likely to be caught at a stage where they can be treated with a simple outpatient procedure [8][4]. Survivorship in the world of esophagitis means living a full life while knowing that a dedicated care team is using evidence-based tools to keep you safe [4].

Back to Home

Common questions in this guide

How often do I need an endoscopy if I have Barrett's esophagus?
For non-dysplastic Barrett's esophagus, guidelines recommend a follow-up endoscopy every 3 to 5 years. If abnormal cells are found, your doctor will likely recommend a much shorter surveillance interval or a minimally invasive treatment.
What is the risk that Barrett's esophagus will turn into cancer?
The annual risk of non-dysplastic Barrett's esophagus progressing to cancer is very low, estimated between 0.1% and 0.3%. Regular monitoring is used to catch any potentially precancerous changes at an early, treatable stage.
How are esophageal strictures treated?
Strictures are typically treated using an outpatient procedure called endoscopic dilation. During this process, a gastroenterologist uses a small balloon or dilator to gently widen the narrowed esophagus, which helps make swallowing easier.
Can my other medications increase my risk for esophageal complications?
Yes, research indicates that certain medications, such as SSRIs and TCAs used for mood and sleep, can increase your risk of developing esophageal strictures. You should always discuss your complete medication list with your gastroenterologist.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the exact length of my Barrett's segment, and how does that influence my surveillance schedule?
  2. 2.Was my biopsy reviewed by a pathologist who specializes in esophageal tissue to confirm the absence of dysplasia?
  3. 3.If I develop a stricture, what are the chances I will need more than one dilation procedure to fix it?
  4. 4.Are my other health conditions, such as chronic kidney disease or the medications I take for mood, increasing my risk of complications?
  5. 5.What specific 'red flags' should I watch for between my scheduled endoscopies?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    The role of endoscopy in the management of gastroesophageal reflux disease.

    Kuribayashi S, Hosaka H, Nakamura F, et al.

    DEN open 2022; (2(1)):e86 doi:10.1002/deo2.86.

    PMID: 35310713
  2. 2

    Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma: Implications for Screening and Surveillance.

    Cook MB, Thrift AP

    Gastrointestinal endoscopy clinics of North America 2021; (31(1)):1-26 doi:10.1016/j.giec.2020.08.001.

    PMID: 33213789
  3. 3

    Diagnosis and Management of Barrett's Esophagus.

    Mejza M, Małecka-Wojciesko E

    Journal of clinical medicine 2023; (12(6)) doi:10.3390/jcm12062141.

    PMID: 36983142
  4. 4

    A narrative review of Barrett's esophagus in 2020, molecular and clinical update.

    Dam AN, Klapman J

    Annals of translational medicine 2020; (8(17)):1107 doi:10.21037/atm-20-4406.

    PMID: 33145326
  5. 5

    Barrett's oesophagus: epidemiology, diagnosis and clinical management.

    Whiteman DC, Kendall BJ

    The Medical journal of Australia 2016; (205(7)):317-24 doi:10.5694/mja16.00796.

    PMID: 27681974
  6. 6

    Optimizing Management of Patients With Barrett's Esophagus and Low-Grade or No Dysplasia Based on Comparative Modeling.

    Omidvari AH, Ali A, Hazelton WD, et al.

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2020; (18(9)):1961-1969 doi:10.1016/j.cgh.2019.11.058.

    PMID: 31816445
  7. 7

    Diagnosis and Management of Low-Grade Dysplasia in Barrett's Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association.

    Wani S, Rubenstein JH, Vieth M, Bergman J

    Gastroenterology 2016; (151(5)):822-835 doi:10.1053/j.gastro.2016.09.040.

    PMID: 27702561
  8. 8

    The evolution of endoscopic therapy for Barrett's esophagus.

    Condon A, Muthusamy VR

    Therapeutic advances in gastrointestinal endoscopy 2021; (14()):26317745211051834 doi:10.1177/26317745211051834.

    PMID: 34708204
  9. 9

    AGA Clinical Practice Guideline on Endoscopic Eradication Therapy of Barrett's Esophagus and Related Neoplasia.

    Rubenstein JH, Sawas T, Wani S, et al.

    Gastroenterology 2024; (166(6)):1020-1055 doi:10.1053/j.gastro.2024.03.019.

    PMID: 38763697
  10. 10

    Esophagogastrectomy for Long-Segment Recurrent Esophageal Stricture Following Hyperemesis Gravidarum.

    Chong Tai LI, Anand G, Singh SP

    Cureus 2023; (15(7)):e42489 doi:10.7759/cureus.42489.

    PMID: 37637565
  11. 11

    Laparoscopic antireflux surgery or PPIs in the management of reflux-related esophageal stricture.

    Li ZT, Kong XL, Zhang R, et al.

    Surgical endoscopy 2023; (37(2)):1077-1085 doi:10.1007/s00464-022-09564-5.

    PMID: 36109360
  12. 12

    Intralesional steroid injections in addition to endoscopic dilation in benign refractory esophageal strictures : a systematic review.

    Henskens N, Wauters L, Vanuytsel T

    Acta gastro-enterologica Belgica 2020; (83(3)):432-440.

    PMID: 33094591
  13. 13

    The Relationship between Gastroesophageal Reflux Disease and Chronic Kidney Disease.

    Wang X, Wright Z, Patton-Tackett ED, Song G

    Journal of personalized medicine 2023; (13(5)) doi:10.3390/jpm13050827.

    PMID: 37240997
  14. 14

    The Use of Antidepressants in Patients With Depression Is Associated With Gastroesophageal Reflux Disease and Disease Severity.

    Saleh S, Fass R

    Neurogastroenterology and motility 2025; (37(6)):e70010 doi:10.1111/nmo.70010.

    PMID: 40033459

This page provides informational guidance on long-term monitoring for peptic esophagitis complications. It does not replace professional medical advice, and you should always discuss your specific surveillance schedule with your gastroenterologist.

Get notified when new evidence is published on peptic esophagitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.